Kitov Pharma (PPBT): Rasio rega marang prakiraan pendapatan
Investments in targeted pancreatic cancer therapy rely on the NT219 license under FDA supervision. The expected price-to-sales ratio on the GURU.Markets chart demonstrates the dynamics of this program, where captures the magnitude of this parameter. An asset-light strategy utilizing outsourced testing scales patents, although regional conflicts create risks for offices and block the export of innovations for Purple Biotech (PPBT).
PPBT (Kitov Pharma): rincian analitis lan laporan miturut indikator
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Purple Biotech|PPBT - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Purple Biotech|PPBT - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Kitov Pharma|PPBT - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Purple Biotech|Likuiditas cepet purple-biotech.com
- data bathi bisnis lan rasio investasi:
PPBT - Penghasilan resik perusahaan|Bathi mangsa ngarep Purple Biotech|PPBT - Rasio rega pasar marang bathi resik|Pangali Forward P/E Purple Biotech Corp|PPBT - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Kitov Pharma|PPBT - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Purple Biotech|PPBT - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan purple-biotech.com|PPBT - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Purple Biotech
- informasi babagan volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:Purple Biotech Ltd. PPBT
The forward P/S ratio compares the market value of Purple Biotech (PPBT) with projected sales, allowing for an assessment of the premium paid for future cash flows. Since the company depends on the outcomes of oncology drug clinical trials without current revenue, the projected P/S trend serves as an indicator of speculative market expectations regarding therapy commercialization and the risk of capital impairment.
Karo sapa Purple Biotech saingan
BeiGene - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan AAPG (Ascentage Pharma Corp)|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan URGN (urogen.com)|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Rasio rega marang prakiraan pendapatan PSNL|Multiplikator Forward P/S ERAS|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AURA|Candel - Multiplikator Forward P/S|ARAY: Rasio rega marang prakiraan pendapatan|SLS: Multiplikator Forward P/S|ACTU - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Citius Oncology, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TuHURA HURA|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|Rasio rega marang pendapatan sing dikarepake FATE|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TScan Therapeutics Inc (TCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Champions Oncology Corp - Multiplikator Forward P/S|XBiotech Inc. (XBIT) - Multiplikator forward rega marang pendapatan|CVM: Multiplikator Forward P/S|OS Therapies Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Artiva - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|VERU: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|Xilio Therapeutics Inc - Rasio rega marang prakiraan pendapatan|RENB: Multiplikator forward rega marang pendapatan|Mural Oncology plc - Rasio rega marang pendapatan sing dikarepake|KAPA: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S Curis Corp|Rasio rega marang prakiraan pendapatan Apollomics, Inc. (APLM)|Tharimmune Corporation - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ADVB (Advanced Biomed)|GNPX - Multiplikator forward rega marang pendapatan|Calidi Bio - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Sunshine Biopharma Inc.|xeneticbio.com (XBIO) - Rasio rega marang prakiraan pendapatan|Salarius Pharma - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan AONC|BGNE: Rega forward marang dodolan|Multiplikator Forward P/S CKPT|Multiplikator forward rega marang pendapatan elevationoncology.com ELEV|iCAD - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Ikena Oncology Inc. IKNA|NTBL - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan VIRX (Viracta Therapeutics)|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
